Ophthalmic Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Ophthalmic Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Ophthalmic Disease Therapeutics Market

The ophthalmic disease therapeutics market size was valued at USD 35.57 billion in 2023, and the market is now projected to grow from USD 37.74 billion in 2024 to USD 62.57 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period of 2024-2032.

The COVID-19 pandemic negatively impacted market increases due to the temporary shutdown of orthopedic clinics and healthcare groups specializing in COVID-19 patients. Lockdown guidelines induced the cancellation or postponement of services for ophthalmic conditions, reducing affected person visits to hospitals and clinics. Consequently, there was a reduced name for ophthalmic sickness therapeutics globally. These elements together slowed market boom all through the forecast length.

The growing occurrence of ophthalmic situations like glaucoma, retinal diseases, and dry eye sickness is using improved name for innovative drugs. These conditions are particularly commonplace most of the geriatric populace, contributing drastically to the growing worldwide affected character populace. As an end result, there may be a heightened need for superior ophthalmic therapeutics to cope with those huge problems.

Rising technological enhancements in drug transport options are using research and improvement towards cutting-edge ocular drug delivery structures. Current demanding situations because of the eye's anatomy and frame shape necessitate advanced answers. This shift in focus among healthcare businesses and marketplace gamers goals to beautify the efficacy and precision of ocular therapeutics. Consequently, innovation in drug transport is becoming a challenge in addressing the ones annoying situations.

Comprehensive Analysis of Ophthalmic Disease Therapeutics Market

The ophthalmic disease therapeutics market growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated by drug class analysis, by dosage form analysis, by disease indication analysis, by distribution channel analysis. By drug class analysis include, anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. By dosage form analysis include, liquid, solid, and semisolid. By disease indication analysis include, glaucoma, dry eye disease, retinal diseases, allergy & infections, and others. By distribution channel analysis include, hospital pharmacies and retail & online pharmacies.

The North America region lead the ophthalmic disease therapeutics market share by benefitting a market size of USD 15.42 billion in 2023 due to growing prevalence of various ophthalmic disorders along with higher diagnosis and treatment rate.

The pinnacle gamers within the marketplace play a critical role in the industry assuring marketplace boom and putting marketplace standards. These players include, Regeneron Pharmaceuticals Inc. (U.S.), AbbVie Inc. (U.S.), Santen Pharmaceutical Co. Ltd. (Japan), Novartis AG (Switzerland), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Viatris Inc. (U.S.) these market players provide a level-playing competitive landscape.

In October 2023, The U.S. FDA approved Genentech’s ophthalmic drug Vabysmo for the treatment of diabetic macular edema.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 6.5% from 2024-2032

Unit Value (USD billion)

Segmentation By Drug Class

Anti-inflammatory

Anti-infectives

Anti-VEGF

Anti-glaucoma

- Beta Blockers

- Prostaglandins Analogs

- Alpha Adrenergic Agonists

- Carbonic Anhydrase Inhibitors

- Combination Drugs

- Others

Others

By Dosage Form

Solid

Liquid

Semisolid

By Disease Indication

Glaucoma

- Open Angle Glaucoma

- Angle Closure Glaucoma

- Others

Dry Eye Disease

Retinal Diseases

- Diabetic Macular Edema (DME)

- Macular Degeneration (AMD)

- Diabetic Retinopathy (DR)

- Retinal Vein Occlusion (RVO)

- Others

Allergy & Infections

Others

By Distribution Channel

Hospital Pharmacies

Retail & Online Pharmacies

By Region

North America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country)

- U.S.

- Canada

Europe (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)

- Germany

- U.K.

- France

- Italy

- Spain

- Scandinavia

- Rest of Europe

Asia Pacific (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)

- China

- Japan

- India

- Australia

- Southeast Asia

- Rest of Asia Pacific

Latin America (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)

- Brazil

- Mexico

- Rest of Latin America

Middle East & Africa (By Drug Class, By Dosage Form, By Disease Indication, By Distribution Channel, By Country/Sub-Region)

- GCC

- South Africa

- Rest of Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.